Narrowband UVB Treatment in Patients With Vitiligo
Not Applicable
Completed
- Conditions
- Vitiligo
- Interventions
- Device: Narrowband UVB
- Registration Number
- NCT00398723
- Lead Sponsor
- Mary Sullivan-Whalen
- Brief Summary
The study offers narrowband UVB light therapy to patients who have 5% of their body involved with vitiligo.
The hypothesis is that Narrowband UVB promotes melanocyte proliferation in vitiligo lesions.
- Detailed Description
All patients will receive phototherapy, with narrowband UVB, three times a week for six months, or a total of 78 treatments. 6mm punch skin biopsies (2) will be done prior to starting therapy, once during treatment (2) and at the completion of the study (2). Clinical assessments and photography will be done parallel to the skin biopsies. Results (clinically and histologically) will be analyzed.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- Age 18 years of age or greater
- Vitiligo with extensive skin involvement (>5% body surface affected).
Exclusion Criteria
- No treatment with topical steroids, calcineurin inhibitors or vitamin D analogs for at least 4 weeks prior to entering the study.
- No treatment with systemic therapies, including methotrexate, etretinate, PUVA, or cyclosporine 4 weeks prior to entering the study.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Vitiligo Narrowband UVB adult patients (age 18 or greater) with extensive vitiligo warranting treatment with whole body NB-UVB
- Primary Outcome Measures
Name Time Method Number of melanocytes per unit length of skin surface pre-treatment, early repigmentation, 75% repigmentation of total body
- Secondary Outcome Measures
Name Time Method Clinical improvement first visit and last visit
Trial Locations
- Locations (1)
Rockefeller University Hospital
🇺🇸New York, New York, United States